FDA-cleared profile

Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR

Canon Medical Systems Corporation · MRI · FDA-cleared (510(k))

Authorized purpose: Vantage Galan 3T systems are indicated as a diagnostic imaging modality producing transaxial, coronal, sagittal, and oblique images of the head or body. The system can also perform non-contrast-enhanced imaging such as MRA. MRI images reflect the spatial distribution of protons and related NMR properties; contrast agents may be used depending on the region, and trained physicians interpret the images.

Clinical role
MRI acquisition, reconstruction, display, and release-specific image processing under professional review.
Images and patients
MRI · Head or body
Key limitation
Keep in mind: Field strength, coils, sequences, anatomy, patient weight, contrast, implant, and optional-feature limits are release-specific; map the installed configuration to the exact labeling.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Vantage Galan 3T systems are indicated as a diagnostic imaging modality producing transaxial, coronal, sagittal, and oblique images of the head or body. The system can also perform non-contrast-enhanced imaging such as MRA. MRI images reflect the spatial distribution of protons and related NMR properties; contrast agents may be used depending on the region, and trained physicians interpret the images.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Head or body Input: MRI signal data acquired with the supported field strength, coils, sequences, contrast, and patient configuration.
  • Who uses it?Intended users: Trained physicians and MRI professionals qualified for the labeled system and applications.
  • What does the software produce?Output: Cross-sectional MR images, spectra, parametric maps, dynamic images, and derived views for professional review.
  • What is its most important limitation?Key limitation: Field strength, coils, sequences, anatomy, patient weight, contrast, implant, and optional-feature limits are release-specific; map the installed configuration to the exact labeling.

Clinical takeaway. Clinical role: Vantage Galan 3T systems are indicated as a diagnostic imaging modality producing transaxial, coronal, sagittal, and oblique images of the head or body. The system can also perform non-contrast-enhanced imaging such as MRA. MRI images reflect the spatial distribution of protons and related NMR properties; contrast agents may be used depending on the region, and trained physicians interpret the images.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports bench testing with a model observer study showing low contrast detectability was maintained or improved, plus SNR and contrast bench testing, and a human observer study with 15 board certified radiologists / cardiologists, a total of 60 subjects and 348 scans that showed a statistical preference for AiCE over other performance filters; AiCE performed at the same level as or above the predicate. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Vantage Galan 3T systems are indicated as a diagnostic imaging modality producing transaxial, coronal, sagittal, and oblique images of the head or body. The system can also perform non-contrast-enhanced imaging such as MRA. MRI images reflect the spatial distribution of protons and related NMR properties; contrast agents may be used depending on the region, and trained physicians interpret the images.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
MRI acquisition, reconstruction, display, and release-specific image processing under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
MRI signal data acquired with the supported field strength, coils, sequences, contrast, and patient configuration.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Cross-sectional MR images, spectra, parametric maps, dynamic images, and derived views for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical MRI departments and other settings where the labeled MRI examinations are performed.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained physicians and MRI professionals qualified for the labeled system and applications.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Field strength, coils, sequences, anatomy, patient weight, contrast, implant, and optional-feature limits are release-specific; map the installed configuration to the exact labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports bench testing with a model observer study showing low contrast detectability was maintained or improved, plus SNR and contrast bench testing, and a human observer study with 15 board certified radiologists / cardiologists, a total of 60 subjects and 348 scans that showed a statistical preference for AiCE over other performance filters; AiCE performed at the same level as or above the predicate. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "AiCE deep learning reconstruction underwent performance (bench testing) using a model observer study to determine that image low contrast detectability was maintained or improved, accompanied with other bench testing of SNR and contrast performance." … "conducted with 15 board certified radiologists / cardiologists and a total of 60 subjects and 348 scans". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports bench testing with a model observer study showing low contrast detectability was maintained or improved, plus SNR and contrast bench testing, and a human observer study with 15 board certified radiologists / cardiologists, a total of 60 subjects and 348 scans that showed a statistical preference for AiCE over other performance filters; AiCE performed at the same level as or above the predicate. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "AiCE deep learning reconstruction underwent performance (bench testing) using a model observer study to determine that image low contrast detectability was maintained or improved, accompanied with other bench testing of SNR and contrast performance." … "conducted with 15 board certified radiologists / cardiologists and a total of 60 subjects and 348 scans". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K203323 FDA decision evidence package for Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR

  • DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
  • PopulationHead or body
  • Scopeexact submission
  • Tested versionVantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR configuration described in K203323
  • IndependenceSponsor or vendor study

K203323

FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K203323 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: MRI signal data acquired with the supported field strength, coils, sequences, contrast, and patient configuration.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K203323: Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Cross-sectional MR images, spectra, parametric maps, dynamic images, and derived views for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K203323: Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional MR images, spectra, parametric maps, dynamic images, and derived views for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K203323: Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.

Training
Only trained physicians and mri professionals qualified for the labeled system and applications should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K203323 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coils, sequences, anatomy, patient weight, contrast, implant, and optional-feature limits are release-specific; map the installed configuration to the exact labeling.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K203323 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Field strength, coils, sequences, anatomy, patient weight, contrast, implant, and optional-feature limits are release-specific; map the installed configuration to the exact labeling.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

exact submission · checked 2026-09-04

No exact-product price or reimbursement determination was promoted.

Lifecycle monitoring

Monitor K203323 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coils, sequences, anatomy, patient weight, contrast, implant, and optional-feature limits are release-specific; map the installed configuration to the exact labeling.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K203323: Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR

    U.S. Food and Drug Administration - Published 2021-03-04 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Canon Medical: Medical Imaging Cybersecurity

    Canon Medical Systems USA - Accessed 2026-10-26

    Scope: security

Research history

  1. K203323 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K202767

Vantage Orian 1.5T, MRT-1550, V6.0

Canon Medical Systems Corporation

Authorized purpose: Vantage Orian 1.5T systems are indicated as a diagnostic imaging modality producing transaxial, coronal, sagittal, and oblique images of the head or body. The system can also perform non-contrast-enhanced imaging such as MRA. MRI images reflect proton density, relaxation, flow, and chemical-shift properties; contrast agents may be used depending on the region, and trained physicians interpret the images.

Modality
MRI
Anatomy
Head or body
Decision
2021-01-15
FDA-cleared K193097

Vantage Orian 1.5T, MRT-1550, V6.0 with AiCE Reconstruction Processing Unit for MR

Canon Medical Systems Corporation

Authorized purpose: Vantage Orian 1.5T systems are indicated as a diagnostic imaging modality producing transaxial, coronal, sagittal, and oblique images of the head or body. The system can perform non-contrast-enhanced imaging such as MRA; contrast agents may be used depending on the region, and trained physicians interpret the images.

Modality
MRI
Anatomy
Head or body
Decision
2020-07-14
FDA-cleared K192574

Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR

Canon Medical Systems Corporation

Authorized purpose: Vantage Galan 3T systems are indicated as a diagnostic imaging modality producing transaxial, coronal, sagittal, and oblique images of the head or body. The system can also perform non-contrast-enhanced imaging such as MRA. MRI images reflect proton density, relaxation, flow, and chemical-shift properties; contrast agents may be used depending on the region, and trained physicians interpret the images.

Modality
MRI
Anatomy
Head or body
Decision
2020-03-09
FDA-cleared K253690

LungMaps

Siemens Healthineers AG

Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.

Modality
MRI
Anatomy
Chest/Lung
Decision
2026-06-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history